CLC3-upregulated cells treated with a2v-mAb exhibited lower apoptosis rates compared to CLC3-downregulated and control cells, indicating that CLC3 modulates V-ATPase activity to enhance cell survival and support tumor growth (Fig. 5C). This evidence concerns the gene CLCN3 and neoplasm.